ASCL2, CMS2, CRC, CRC patient-derived xenograft models, CpG-rich promoters, EGFRi, EpiC, EpiC subgroups, FZD10, H3K27ac, H3K27me3, H3K4me1, H3K4me3, H3K79me2, H3K9me3, MEK, PARPi, Pol II, TGFi, active enhancer, adenomas, chromatin, colon cancer, colon cancer cell lines, colorectal adenocarcinomas, colorectal cancer, colorectal cancers, consensus, enhancer, enhancer patterns, enhancer subtypes, enhancers, heterochromatin, mTORi, oncogenes, patient, poised enhancers, polycomb, polycomb repressed regions, transcribed regions, transcriptionally active promoters, tumour, tumour-specific enhancers